OABI News
OmniAb to Report Third Quarter 2026 Financial Results on October 30
OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced the Company will report financial results for the three and nine months ended September 30, 2026, before the open of the U.S. financial...
Business Wire
OmniAb to Report Third Quarter 2026 Financial Results on October 30
OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced the Company will report financial results for the three and nine months ended September 30, 2026, before the open of the U.S. financial...
Business Wire
All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to Buy
OmniAb, Inc. (OABI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
OmniAb Highlights Partner Pipeline, xPloration Plans and Outlook, and Introduces the OmniTides Platform at Investor & Analyst Day
OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today hosts its Investor & Analyst Day in Emeryville, CA. With a full presentation agenda, the event highlights recent partner developments, the broader...
Business Wire
OmniAb to Host Investor & Analyst Day on October 6, 2026
OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today reiterates details of its upcoming Investor & Analyst Day, to be held on October 6, 2026, in Emeryville, CA. The event will feature presentations from...
Business Wire
OmniAb to Participate in Upcoming Investor Conferences
OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced managements participation in the following upcoming investor conferences: Nasdaq/LD Micro Summit Series Date: Wednesday, September 9, 2026...
Business Wire
The Nasdaq Stories Traders Can't Ignore
Here are today’s catalysts that are changing the narrative. $NTHI, $IPST, $OABI, $LLY, $HIVE, and $IVF
24-7 Market News
Why Is Omniab Stock Rallying After Eli Lilly Deal?
The OmniAb Lilly Deal offers up to $370 million in milestones as OABI raises its 2026 cash outlook and shares jump premarketread more...
Benzinga
OmniAb Lands Lilly and Raises Guidance: $370M Deal Puts OABI’s Discovery Platform in the Spotlight
OmniAb (NASDAQ:OABI) may be one of the more interesting picks-and-shovels stories emerging in biotech, and its latest deal with Eli Lilly & Company (NYSE:LLY) could be another indication that the pharmaceutical industry sees value in the company’s technology rather than simply another early-stage drug program.
24-7 Market News
OmniAb Raises 2026 Financial Guidance
OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today raised its 2026 cash and cash equivalents financial guidance following recent technology licensing activity. Recent business development and licensing...
Business Wire
OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company
OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced a global collaboration and license agreement with Eli Lilly and Company (Lilly) for a new ion channel program. The collaboration leverages...
Business Wire